title: Effect of intra-hepatoarterial infusion of MMC and CDDP for gastric cancer patients with liver metastases.
abstract: The influence of operative treatment and chemotherapy on the prognosis in 93 gastric cancer patients with liver metastasis was studied. Chemotherapy included the systemic administration of mitomycin C (MMC) (39 patients), an intra-hepatoarterial infusion of MMC (MMC IAC group) (19 patients) and an intra-hepatoarterial infusion of MMC and cisplatin (CDDP) (MMC + CDDP IAC group) (24 patients). Either MMC or MMC and CDDP were given in 1-4 courses every 3-4 weeks from the first one to two post operative weeks. The response rate was 4 per cent (1/23), 29 per cent (5/17) and 73 per cent (17/23) for MMC systemic administration, MMC IAC and MMC + CDDP IAC, respectively, with a significantly high rate of effectiveness for the MMC + CDDP IAC. In addition, regarding the median survival period, the MMC + CDDP IAC group showed 11.8 months, as compared with 2.9 months for other chemotherapeutic treatments, indicating a good prognosis regardless of any possible resection of the primary lesion. A Cox proportional hazard model revealed the treatment by MMC + CDDP IAC alone to be a significant independent factor. These results indicated that MMC + CDDP intra-arterial chemotherapy is an effective approach to gastric cancer with liver metastasis.
authors.affiliation: Department of Surgery II, School of Medicine, Kanazawa University, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Yonemura
authors.forename: N
authors.initials: N
authors.lastname: Matuki
authors.forename: H
authors.initials: H
authors.lastname: Sakuma
authors.forename: K
authors.initials: K
authors.lastname: Katayama
authors.forename: T
authors.initials: T
authors.lastname: Sawa
authors.forename: T
authors.initials: T
authors.lastname: Fujimura
authors.forename: S
authors.initials: S
authors.lastname: Ohyama
authors.forename: K
authors.initials: K
authors.lastname: Miwa
authors.forename: I
authors.initials: I
authors.lastname: Miyazaki
authors.forename: M
authors.initials: M
authors.lastname: Tanaka
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006499:Hepatic Artery; D006801:Humans; D007261:Infusions, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D016016:Proportional Hazards Models; D013274:Stomach Neoplasms / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D015996:Survival Rate
chemical_list: D016685:Mitomycin; D002945:Cisplatin